GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (FRA:IMR) » Definitions » Inventories, Other

AC Immune (FRA:IMR) Inventories, Other : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is AC Immune Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. AC Immune's other inventories for the quarter that ended in Sep. 2024 was €0.00 Mil.


AC Immune Inventories, Other Historical Data

The historical data trend for AC Immune's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Inventories, Other Chart

AC Immune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AC Immune Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AC Immune Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


AC Immune Business Description

Traded in Other Exchanges
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune Headlines

No Headlines